| |
|
|
|
| |
Basic InformationMore InformationLatest NewsDiuretics Still Best Treatment for High Blood PressureNewer Blood Thinners May Outperform Old StandbysHeart Failure Drug May Help More in Higher DosesHeartburn Drugs Can Thwart Popular Blood ThinnerTrivalent Vaccine Has Minimal Effect on H1N1Qutenza Approved for Post-Shingles Nerve PainAHA: Meditation Found Helpful in Coronary Heart DiseaseDrug May Reverse Type 1 Diabetes Ocular ComplicationsStudy Raises New Questions About Cholesterol Drug ZetiaAlternative to Warfarin May Cut Risk of Bleeding'The Pill' May Reduce Asthma SymptomsEarly Treatment Needed for Drug-Induced HypertensionPneumonia Drug Promising Against Form of Muscular DystrophyLeukemia Drug May Help Some Ovarian Cancer PatientsTrial Data on Anti-Seizure Drug Might Have Been Manipulated: ReportAnemia Drugs May Cause Deadly Blood ClotsEarly Use of NSAIDs Might Prevent Alzheimer'sArthritis Drugs Unlikely to Increase Cancer RiskBreast Cancer Drugs May Fight Cervical Cancer, TooMost Who Want Swine Flu Shot Can't Get ItClinical Trials Update: Nov. 6, 2009Health Tip: Follow Directions When Taking MedicationClinical Trials Update: Nov. 5, 2009Drug May Boost Hemoglobin in Chronic Kidney DiseaseAspirin May Not Help Prevent Primary Heart DiseaseWill New Anemia Drug Top Current Treatments?FDA Initiative Seeks to Reduce Accidental OverdosesClinical Trials Update: Nov. 4, 2009How Safe Are Popular Reflux Drugs?FDA Warns Exenatide Could Cause Kidney ProblemsClinical Trials Update: Nov. 3, 2009CDC Study Links 2 Antibiotics to Birth DefectsClinical Trials Update: Nov. 2, 2009Antibiotic Resistance Still a Major Public Health ThreatCholesterol Drugs May Help Prevent Flu DeathsClinical Trials Update: Oct. 29, 20091 Million More Doses of Swine Flu Vaccine on HandClinical Trials Update: Oct. 28, 2009FDA: Arzerra Approved for Chronic Lymphocytic LeukemiaAntipsychotic Drugs Can Cause Pediatric Weight GainMore Swine Flu Vaccine Coming SoonClinical Trials Update: Oct. 27, 2009Far Fewer H1N1 Vaccine Doses Than Expected Are AvailableHPV Vaccine No More Painful Than Other ShotsAdding Drug Doesn't Help Control Blood PressureClinical Trials Update: Oct. 23, 2009Guidelines Urge Use of Erectile Dysfunction DrugsClinical Trials Update: Oct. 22, 2009Novel H1N1 Vaccine Found Effective for Most Age GroupsWorldwide Vaccine Availability Reaches All-Time High: Report Questions and AnswersBlog EntriesVideosLinksBook Reviews |
| | | |
Arthritis Drugs Unlikely to Increase Cancer Risk(HealthDay News) by -- A. Agrawal, PhD Updated: Nov 9th 2009
MONDAY, Nov. 9 (HealthDay News) -- Rheumatoid arthritis (RA) patients who start taking anti-tumor necrosis factor α (anti-TNFα) drugs are not likely to have a higher risk of developing cancer than other groups of RA patients, according to a Swedish study in the November issue of Arthritis & Rheumatism.
Johan Askling, M.D., of Karolinska University Hospital at Solna in Stockholm, Sweden, and colleagues compared the risk of cancer in 6,366 RA patients newly being prescribed anti-TNFα treatment, 61,160 biologics-naive RA patients, 5,989 RA patients being prescribed methotrexate, 1,838 RA patients starting disease-modifying antirheumatic drug combination therapy, and the general population of Sweden.
During 25,693 person-years of follow-up, the researchers diagnosed 240 first cancers among RA patients taking anti-TNFα drugs. The risk of cancer was similar in all four groups of RA patients, with a relative risk of approximately 1.0. The relative risks did not increase with increasing time since starting anti-TNFα treatment or the total treatment time. During the first year of treatment, there was a lower risk of cancer in patients who first took etanercept and a higher risk in patients who first took infliximab or adalimumab, but these differences disappeared after one year.
"During the first six years after the start of anti-TNF therapy in routine care, no overall elevation of cancer risk and no increase with follow-up time were observed," the authors conclude.
ARTIS, the Swedish Biologics Register, which supported the study, received maintenance funding from several pharmaceutical companies, and several of the authors reported financial and consulting relationships with pharmaceutical companies.
Abstract
Full Text (subscription or payment may be required)
This article: Copyright © 2009 ScoutNews, LLC. All rights reserved. |
| 







|
|
|
|
|
|